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The RNA-binding protein HuD promotes neurogene-
sis and favors recovery from peripheral axon injury.
HuD interacts with many mRNAs, altering both sta-
bility and translation efficiency. We generated a
nucleotide resolution map of the HuD RNA interac-
tome in motor neuron-like cells, identifying HuD
target sites in 1,304 mRNAs, almost exclusively in
the 30 UTR. HuD binds many mRNAs encoding
mTORC1-responsive ribosomal proteins and trans-
lation factors. Altered HuD expression correlates
with the translation efficiency of these mRNAs and
overall protein synthesis, in a mTORC1-independent
fashion. The predominant HuD target is the abun-
dant, small non-coding RNA Y3, amounting to
70% of the HuD interaction signal. Y3 functions as
a molecular sponge for HuD, dynamically limiting
its recruitment to polysomes and its activity as a
translation and neuron differentiation enhancer.
These findings uncover an alternative route to the
mTORC1 pathway for translational control in motor
neurons that is tunable by a small non-coding RNA.
INTRODUCTION
The intensively studied RNA-binding protein (RBP) human anti-
gen D (HuD)/embryonic lethal, abnormal vision like 4 (ELAVL4)
is predominantly expressed in differentiated neurons, as are
the other neuronal members (nELAV) of the ELAV family, HuB256 Molecular Cell 71, 256–270, July 19, 2018 ª 2018 The Authors. P
This is an open access article under the CC BY license (http://creative(ELAVL2) and HuC (ELAVL3). In contrast, HuR (ELAVL1) is ubiq-
uitously expressed (Pascale et al., 2008). HuD carries three RNA
recognition motif (RRM) domains and plays important roles in
controlling the fate of many neuronal mRNAs. Functional ana-
lyses implicate HuD in the regulation of mRNA stability, alterna-
tive splicing, alternative polyadenylation, RNA localization, and
translation (Bronicki and Jasmin, 2013).
HuD is one of the first markers expressed during neuronal
differentiation and plays a fundamental role in controlling
neuronal cell fate. Loss of HuD induces increased self-renewal
of the neural stem and progenitor cells (Akamatsu et al., 2005),
whereas overexpression promotes neurite outgrowth, neuro-
genesis, and neuronal plasticity (Perrone-Bizzozero and Bolog-
nani, 2002).
Importantly, HuD is specifically implicated in motor neuron
function, and HuD knockout mice show motor deficits (Aka-
matsu et al., 2005), while regeneration following peripheral
axon injury is associated with increased levels of HuD and of
its target GAP43 (Anderson et al., 2003). Recent studies pointed
out the intimate relationship between HuD andmotor neuron dis-
eases. HuD has been characterized for its ability to localize
mRNAs in primary motor neurons and restore axon outgrowth
defects in spinal muscular atrophy (SMA) motor neurons (Akten
et al., 2011; Fallini et al., 2011). Moreover, cytoplasmic inclusions
of TDP-43, a pathological hallmark of amyotrophic lateral scle-
rosis (ALS), are proposed to sequester HuD (Fallini et al., 2012).
To understand the molecular mechanism that underpins the
functions of HuD, we first sought to positionally identify its
RNA targets in a comprehensive way. Selective antibodies for
individual nELAV paralogs are currently not available, so cross-
linking and immunoprecipitation (CLIP) analysis identified
only RNAs cumulatively bound to nELAV proteins HuB, HuC,
and HuD (Scheckel et al., 2016). Specific HuD targets wereublished by Elsevier Inc.
commons.org/licenses/by/4.0/).
previously identified by immunoprecipitating HuD from a HuD-
overexpressing mouse (Bolognani et al., 2010). However, this
approach could not provide positional information on the binding
sites on RNA or distinguish between direct and indirect targets.
To overcome these limitations, we specifically characterized the
RNA interactome of HuD using the CRAC (cross-linking and
analysis of cDNAs) method (Granneman et al., 2009). We per-
formed our analysis in NSC-34 cells, which recapitulate motor
neuron phenotypes in vitro.
We found that HuD directly and specifically enhances the
translation efficiency of mRNAs known to be involved in motor
neuron differentiation and axonogenesis. Surprisingly, we also
found that a major HuD-bound cluster contains mRNAs encod-
ing components of the translational machinery. HuD translation
enhancer activity is independent from the major pathway
affecting general translation, controlled by the mTORC1 com-
plex, despite targeting an overlapping set of mRNAs.
Remarkably, the Y3 small noncoding RNA (ncRNA) was by far
the strongest HuD binding partner. Y RNAs are abundant
ncRNAs transcribed by RNA polymerase III (Ko¨hn et al., 2013;
Kowalski and Krude, 2015), ranging in size from 70 to 115 nt
and folding into characteristic stem-loop structures. Y RNAs
were proposed to be involved in DNA replication and histone
mRNA processing (Ko¨hn et al., 2015). However, their biological
functions are still largely elusive. Here, we demonstrate that Y3
acts as a molecular sponge for HuD activity, by competing
with HuD target mRNAs and by limiting HuD access to the poly-
somal compartment.
RESULTS
Identification of the HuD RNA Interactome in a Motor
Neuron Cell Line
HuD shares a high sequence and structure similarity with the
other members of the ELAV family, and all available antibodies
fail to distinguish among them. To overcome this difficulty, we
adapted the CRAC protocol to be used with mouse motor
neuron NSC-34 cells engineered with doxycycline-inducible
His-HA tagged HuD. We performed the CRAC experiment using
doxycycline at 2 ug/ml for 48 hr to limit HuD levels to physiolog-
ical values (Figures S1A–S1C). We used doxycycline-treated
cells expressing only the tetracycline receptor (Trex cells) as
control for the aspecific signal (Figure 1A and STAR Methods).
To precisely map the HuD RNA interactome, we developed
a dedicated computational methodology (see also STAR
Methods). This approach takes advantage of cross-linking
induced mutations—primarily micro-deletions—to identify
candidate binding sites with nucleotide resolution (Figure 1B).
To increase specificity, we penalized locations with aligned
reads in control experiments. We selected a set of 753 se-
quences surrounding locations with p value <0.05 to build a po-
sitional weightmatrix (PWM). This ‘‘seed’’ PWMwas defined on a
region spanning 7 nt around the deletion site (Figure S1D). The
size choice is based on previous crystallographic studies
resolving the structure of the RRM1 and RRM2 domains of
HuD bound to canonical AU rich elements (Wang and Tanaka
Hall, 2001). We used the seed PWM to score all the other candi-
date binding sites and select high-confidence HuD bound sites,with the advantage of identifying in this way interaction sites
even in transcripts with low expression levels. The strength of
this methodology is revealed by the comparison between the
distribution of scores associated with CRAC deletion sites and
the distribution of random sequences (Figure 1C). The experi-
mental distribution is peaked above the threshold score corre-
sponding to the 95th percentile of the random distribution.
We performed parallel RNA-Seq in NSC-34 cells to quantify
the steady-state levels of transcripts. Of note, HuD binding site
intensities showed a low positive correlation with transcript
levels (measured by FPKM, Pearson correlation = 0.24) (Fig-
ure S1E). Binding affinity could therefore be the main factor
influencing peak intensity. We normalized CRAC binding site
intensities for transcript levels, and we created a logo represen-
tation where each HuD binding site is weighted for its binding
affinity (Figure 1D). The core of the resulting HuD affinity logo
contains a triplet of U nucleotides (weight = 1), preceded by a
non-U nucleotide with the following weights in decreasing order:
C (weight = 0.40), A (weight = 0.32), and G (weight = 0.28). This
result suggests that HuD binding affinity is similarly strong for
canonical AU-rich elements (AUUU); GU-rich elements (GUUU,
also reported as the main nELAV binding site in Scheckel
et al., 2016); and in particular CU-rich elements (CUUU). Of
note, CU-rich and GU-rich related elements were indirectly iden-
tified as HuD binding motifs also in Bolognani et al. (2010).
Our approach detected 5,153 high-confidence binding re-
gions, mapped on 1,304 protein coding genes and 131 ncRNAs
(Figure 1E; Table S1). Among the ncRNAs, 10 were long inter-
genic ncRNAs (lincRNAs) including Neat1, Malat1, and Yam1,
known to be involved in cell-fate programming. Strikingly, the
by far predominant HuD binding sites were found on the Y3 small
ncRNA, representing 70% of all binding signal (Figure 1E).
We further validated interactions identified by CRAC with
RNA immunoprecipitation (RIP) for 70 mRNAs and for the Y3
RNA. For the mRNAs tested, RIP followed by targeted
sequencing confirmed the identification of bona fide HuD bind-
ing sites by CRAC, with a median log2 fold enrichment of 5.8
(Figure 1F; Table S2). We selectively enriched Y3 together
with the positive control Bdnf mRNA in HuD ribonucleoprotein
particles, but not in negative control cells (Figure 1G, left panel).
For both conditions, no binding to the Rpl10a transcript (nega-
tive control mRNA) was detected. His-tag non-specific interac-
tions were excluded by additional RIP assays in NSC-34 cells
overexpressing His-HA-GFP or with a reduced HuD induction
(Figure S1F). The interaction between HuD and Y3 was further
confirmed in NSC-34 transiently transfected with SBP-tagged
HuD (Figure 1G, right panel). No binding was detected for the
Y1 small ncRNA, the only other member of the Y RNA family
in the mouse genome, nor for the highly abundant small
ncRNA signal recognition particle RNA (7SL). Additionally, we
performed a pull-down assay by using Y3, Y1 and human Y4
(hY4) ncRNAs, as synthetic biotinylated probes, in both NSC-
34 induced for HuD and in control cells. We demon-
strated specific association between HuD and Y3 (Figure 1H,
right panel).
In summary, we reliably profiled the HuD RNA interactome in
NSC-34 cells, identifying the Y3 ncRNA as the by far most repre-
sented target.Molecular Cell 71, 256–270, July 19, 2018 257
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Figure 1. Defining the RNA Interaction Landscape of HuD in Motor Neuron Cells
(A) Schematic representation of CRAC performed on motor neuron NSC-34 cells.
(B) Identification of HuD binding sites from CRAC data.
(C) Distribution of HuD PWM scores, calculated from CRAC deletion sites (in violet) and compared with random sequences (in gray). The score threshold to
identify bona-fide binding sites was set as the 95th percentile of the random distribution (vertical dashed line).
(D) Logo representation of HuD binding sites weighted by binding affinity, calculated as CRAC binding intensities scaled for transcript expression levels.
(E) Pie charts displaying the number of HuD RNA targets (upper panel) and the corresponding interaction weight (percentage of CRAC intensity, lower panel) for
distinct RNA species.
(F) Validation by RNA immunoprecipitation (RIP) and targeted sequencing of 70 HuD targets identified by CRAC.
(G) Validation of HuD-Y3 interaction by alternative approaches: left panel, RIP assay followed by Northern blots in HuD transfected NSC-34 cells; right panel, RIP
assay followed by RT-qPCR in NSC-34 HuD-inducible cells and in Trex NSC-34 cells (control). In (G), data are represented as mean ± SEM; t test: *p < 0.05,
**p < 0.01.
(H) Streptavidin pull-down of synthetic biotinylated YRNAs (Y3, Y1, and human Y4) followed bywestern blot analysis in NSC-34 cells induced for HuD expression.
The La (SSB) and Vinculin (VCL) proteins were used as positive and negative control proteins, respectively, for binding to Y RNAs.
See also Figure S1 and Table S1.
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Figure 2. HuD Increases Global and Target-Specific Translation
(A) Top enriched Gene Ontology terms among HuD mRNA targets are related to RNA processes, including splicing, transport, stability, and translation
(highlighted in bold).
(B) Metaprofile of HuD binding sites along protein coding transcripts, showing binding enrichment in 30UTRs.
(C) Right panel: representative sucrose gradient profiles in control and HuD overexpressing NSC-34 cells. Left panel: calculation of the global translation
efficiency upon HuD silencing and overexpression.
(D) Right: schematic representation of Click-iT AHA assay to quantify de novo protein synthesis in NSC-34 cells. Left: detection of de novo protein synthesis upon
HuD silencing and overexpression. Puromycin, a translation inhibitor, was used as negative control.
(legend continued on next page)
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HuD Enhances the Translation of Target Translation
Factors
To provide a functional characterization of HuD-interacting
RNAs, we performed enrichment analysis of Gene Ontology
(GO) terms and pathways (Figure 2A). We identified significant
enrichments for terms related to genes involved in mRNA pro-
cessing and translation: 80 genes, including 34 ribosomal com-
ponents and 12 translation initiation or elongation factors. Within
mRNA targets, HuD binding sites were predominantly located in
the 30 UTR of protein coding transcripts (92%), consistent with
functions in translation (Figure 2B).
The widespread HuD binding to mRNAs encoding ribosomal
proteins and translation factors suggested that HuD could indi-
rectly promote global translation through the post-transcrip-
tional modulation of these mRNAs. We therefore assessed
the role of HuD in modulating global translation by polysome
profiling in NSC-34 cells with the overexpression or silencing of
HuD (Figures S2A and S2B). The global translation efficiency
(TE) of the cells was calculated as the ratio between the absor-
bance of polysomes and the total absorbance of non-translating
80S ribosomes (see STAR Methods and Figure 2C). As shown in
Figure 2C, HuD overexpression significantly increased the global
TE of NSC-34 cells. Conversely, HuD depletion by RNA interfer-
ence resulted in a reduced global TE. To support this finding, we
assessed the ability of HuD to promote de novo protein synthesis
by metabolic labeling (see STARMethods). Wemeasured a sub-
stantial increase (about 2-fold) in overall de novo protein synthe-
sis in HuD-overexpressing cells compared to control cells,
whereas knockdown of HuD resulted in de novo protein synthe-
sis reduction (Figure 2D).
We further confirmed the role of HuD as a translational
enhancer of its targets by combining RNA-Seq and POL-Seq
(polysomal RNA sequencing) of NSC-34 cells upon HuD overex-
pression (Figure 2E). Translation efficiency was defined for each
gene as the ratio between POL-Seq and RNA-Seq levels. Impor-
tantly, HuD targets were strongly enriched in genes with
increased translation efficiency (fold enrichment = 3.6, p value =
7.6e-10) and, conversely, underrepresented in genes with
decreased translation efficiency (Figure 2F, right panel). This
level of enrichment was observed only combining translatome
and transcriptome variations and derived mainly from transla-
tome effects (Figure 2F). On the other hand, transcriptome-
wide alternative polyadenylation (APA) analysis upon HuD
overexpression didn’t reveal an enrichment of HuD targets
among genes with differentially used polyadenylation sites (Fig-
ures S2D–S2G).
To investigate the mechanism through which HuD promotes
translation, we focused on translation factors identified as HuD(E) Transcriptome-wide translation efficiency changes upon HuD overexpression
signal (CPM) against the log2 change in translation efficiency (delta TE) upon Hu
(F) Enrichment analysis of HuD RNA targets among genes with increased or decre
genes changing at either the polysomal or the total RNA level. Fisher’s test *p <
(G) Enrichment of mTOR responsive mRNAs among HuD targets, as listed in mu
(H) Western blot analysis of HuD targets (Eef1a1, Eif4a1, Eif4a2, Pabpc1) and neg
was used as reference. Experiments were performed at least in triplicate.
In (C), (D), and (H), data are represented as mean ± SEM; t test *p < 0.05, **p < 0
See also Figure S2.
260 Molecular Cell 71, 256–270, July 19, 2018targets by the CRAC analysis. Notably, many of these factors
are known to be mTOR responsive (Hsieh et al., 2012; Larsson
et al., 2012; Thoreen et al., 2012), including 50-TOP or 50-TOP-
like mRNAs (Meyuhas and Kahan, 2015) (Figure 2G). Among
these mRNAs, we selected for validation the translation elonga-
tion factor Eef1a1, the cytoplasmic poly(A) binding protein
Pabpc1, and the eukaryotic initiation factors Eif4a1 and Eif4a2.
Eef1a1, Pabpc1, Eif4a1, and Eif4a2 mRNAs are strongly bound
by HuD in their 30 UTRs (Figure S2C). As shown in Figure 2H,
overexpression of HuD significantly increased the protein levels
of Eef1a1, Pabpc1, Eif4a1, and Eif4a2 with respect to tubulin. As
negative control we used the exon junction complex component
Eif4a3, which is a recognized Eif4a1 and Eif4a2 paralog, but
neither a HuD target nor a TOP gene. Levels of Eif4a3 were un-
affected by enhanced HuD expression.
HuD Translation Enhancement Activity Does Not
Depend on the mTORC1 Pathway
Since mTOR-responsive genes were significantly enriched
among HuD targets (Figure 2G), we next assessed if the HuD-
dependent boost to global and target specific translation was
mediated through the mTORC1 pathway. We serum starved
cells to decrease activity of the mTORC1 pathway to less than
50%, as assessed by the phosphorylation status Eif4ebp1 and
Rps6. This treatment did not affect the levels of endogenous
HuD or inducible His-HA-HuD (Figure 3A) and did not induce
the formation of P-bodies or stress granules (Figure S3A) in
NSC-34 cells. We then measured global TE by polysome
profiling. As expected, starvation caused a decrease in the
global TE compared to serum-repleted cells. Interestingly, HuD
overexpression restored and even increased TE in serum-
depleted cells relative to repleted cells (Figure 3B). HuD overex-
pression also efficiently suppressed the effects of the mTORC1
inhibitor Torin1 (Figure S3B). We selected different classes of
mTOR-responsive, HuD-bound mRNAs for TE quantification by
qPCR: ribosomal proteins, polyadenylation factors, translation
elongation, and initiation factors. The results consistently proved
that HuD overexpression increased the TE of these target
mRNAs upon starvation (Figure 3C), whereas Eif4a3 was unaf-
fected. We further verified that the increase in TE correlated
with enhanced Eef1a1 protein levels, with no effect on the nega-
tive control Eif4a3 (Figure 3D).
These results indicate that increased HuD activity is able to
rescue global and target-specific translation inhibition exerted
by partial suppression of mTORC1 pathway signaling. To
confirm this, we further explored how HuD regulates the expres-
sion of the 50 TOP gene Eef1a1, known to be selectively modu-
lated by mTORC1. We cloned the 30 UTRs of Eef1a1 and thein NSC-34 cells. Scatterplot displaying for each gene the average expression
D overexpression. Genes with increased or decreased TE are highlighted.
ased TE upon HuD overexpression, compared to enrichments associated with
0.05, **p < 0.01, and ***p < 0.001.
ltiple literature sources.
ative control (Eif4a3) in HEK293 cells transiently transfected with HuD. Tubulin
.01, and ***p < 0.001.
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Figure 3. HuD Enhancement of Global and
Target-Specific Translation Efficiency Does
Not Depend on the mTORC1 Pathway
(A) Left: western blot analysis of Rps6 and Eif4ebp1
phosphorylation following serum deprivation (8 hr) in
NSC-34 cells.
(B) Measurement of global TE by sucrose
gradient centrifugation in the following conditions:
control, starvation, and starvation coupled with HuD
overexpression.
(C) TE quantification of selected mTOR-responsive
mRNAs in control, starvation, and starvation
coupled with HuD overexpression conditions.
Target-specific TE is the ratio between polysomal
and total RNA changes measured by RT-qPCR.
Gapdh and Als2 were used as reference genes.
(D) Western blot analysis of Eef1a1 and Eif4a3 in
NSC-34 cells collected in three different condi-
tions: control, starvation, and starvation with HuD
overexpression.
(E) Barplot displaying normalized luciferase intensity
values in HEK293 cells transiently transfected with
HuD, relative to transient transfection of the empty
vector. Cells were co-transfected with wild-type
(WT) or mutated (MUT) TOP motif bearing luciferase
vectors with the 30UTR of Eef1a1 (HuD target) or
Eif4a3 (negative control).
In (A)–(E), data are represented asmean ± SEM t test
*p < 0.05, **p < 0.01, and ***p < 0.001. In (A)–(C),
‘‘Starvation’’ was compared to ‘‘Control,’’ and
‘‘Starvation + HuD overexpression’’ was compared
to ‘‘Starvation’’ for testing statistical significance.
See also Figure S3.negative control Eif4a3 downstream of luciferase, in a reporter
vector harboring a canonical TOP motif at the 50 end (Thoreen
et al., 2012). We expressed these reporters alone or in combina-
tion with HuD in HEK293 cells, not expressing endogenous HuD.
Luciferase activity was enhanced by HuD co-expression in the
case of the vector carrying the 30 UTR from Eef1a1, but not for
Eif4a3 (Figure 3E). Importantly, we obtained the same results
when using a luciferase vector with a mutated TOP motif not re-
sponding to mTOR signaling (MUT-TOP; Thoreen et al., 2012), in
the 50 UTR (Figure 3E). These results collectively demonstrate
that the translational control exerted by the mTORC1 pathway
on 50 UTR TOPmRNAs can be independently tuned by the trans-
lational enhancement promoted by HuD through binding to the
30 UTR.
HuD Stimulates the Translation of mRNAs Involved in
Neuronal Fate Commitment and in Axonogenesis
Control of translation is a key step in mediating neuronal activity
and synaptic plasticity. HuD was demonstrated to induce
neuronal differentiation, acting on specific neuronal target
mRNAs (Descheˆnes-Furry et al., 2007).
We identified as high-confidence hits multiple neuronal
mRNAs previously reported to interact with HuD (Table S1).
These included Gls, Ikzf5, Lmo4, Marcks, Msi1, Nova1, Nrn1,
App, and Atg5 (Akten et al., 2011; Bronicki and Jasmin, 2013;Kang et al., 2014). Analysis of mRNAs responsible for neuronal
specification in the CRAC data revealed enrichment for genes
involved in neuronal differentiation and neurogenesis, and genes
involved in axonogenesis, axon guidance, myelin deposition,
axon localization, and synaptic functionality (Figure S3C). To
assess whether HuD binding to these mRNAs results in pheno-
typic effects on neurogenesis, we induced HuD overexpression
in differentiating NSC-34 cells. We observed a significant in-
crease in neuronal outgrowth in HuD overexpressing cells
compared to control cells (Figure S3D). We also confirmed that
HuD promotes neurite extension in PC12 cells (Fukao et al.,
2009), and that this ability is preserved by two HuD isoforms
(HuD-sv1 and HuD-sv2), as reported by Hayashi et al. (2015)
(Figure S3E).
Next, we inspected whether HuD expression correlated with
enhanced TE for 11 selected HuD target mRNAs, known to
play important roles in motor neurons and axons. As shown in
Figure S4F, we found a significant TE increase in HuD overex-
pressing cells for each of these mRNAs. The increase was
greater for Kif5b, Sema4d, Picalm, Acsl4, and Hnrnpa2b1. TE
enhancement upon HuD overexpression was driven by
increased polysomal occupancy, with almost no variation in total
RNA levels. We then examined the overlap between HuD binding
targets and mRNAs with altered expression in motor neuron dis-
eases (Figure S3G). We observed a strong enrichment for motorMolecular Cell 71, 256–270, July 19, 2018 261
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Figure 4. Y3 Competes for HuD Association with Target mRNAs
(A) Upper panel: secondary structure of Y3 with HuD interaction sites (visualized with VARNA) based on chemical probing. Center panel: representation of the Y3
‘‘deleted’’ variant, obtained by eliminating the conserved HuD binding region. Lower panel: His-HA-HuDwas induced in NSC-34 cells. Lysates were subjected to
RNA pull-downs with biotinylated Y3, followed by immunoblot for HuD and La proteins. Either the wild-type Y3 sequence or themutant that lacks the HuD binding
site was used.
(B) Y3 RNA-pull-down showing that HuD interacts with Y3 by the RRM domains, mainly RRM1 and RRM2.
(C) Quantification of Y3 and HuD molecule number in NSC-34 cells. The estimated molecule number was calculated by means of a calibration plot generated by
known amounts of standards, i.e., in vitro-transcribed (ivt) Y3 RNA and recombinant HuD, respectively.
(legend continued on next page)
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neuron disease-associated genes among HuD targets, and we
confirmed the effects of HuD overexpression on translation for
specific genes associated with ALS and genes with altered
expression in both ALS and SMA (Figure S3H). This observation
highlights a potential role for HuD inmodulating the expression of
pathologically relevant transcripts in motor neurons.
Y3 Competes for HuD Binding against mRNAs
Quantitative analysis of the CRAC interactions clearly identified
the 102 nt ncRNA Y3 as the largely dominant HuD target. Inspec-
tion of the CRAC deletion profiles revealed two binding sites in
Y3 that map to loop regions closely positioned in the secondary
structure (Teunissen et al., 2000) (Figures 4A and S4A). From an
analysis of sequence evolutionary conservation, which
confirmed previous literature (Farris et al., 1995), we found that
the first Y3 HuD binding region (nt 20–25) is markedly less
conserved than the second (nt 55–70). Based on this result,
we generated a Y3 ‘‘deleted’’ variant by eliminating the
conserved HuD binding region (Figure 4A). This variant is unable
to interact with HuD, as assessed by RNA pull-down (Figure 4A,
lower panel).
Similarly, we determined the region of HuD involved in Y3
binding. We transfected NSC-34 cells with four different HuD
constructs (Fukao et al., 2009): (1) wild-type (WT); (2) HuD-
MUT, lacking any RNA-binding activity; (3) HuD-14-302, lacking
RRM3, the HuD RNA binding domain proposed to bind the
poly(A); and (4) HuD-216-385, lacking the RNA binding domains
RRM1 and RRM2. By Y3 pull-down, we found that the HuD RRM
domains are necessary for the interaction with Y3, with a stron-
ger contribution of the first and the second RRMs (Figure 4B).
After having established the molecular details of the HuD/Y3
interaction, we investigated their relative stoichiometry in cells.
Using calibration curves, we estimated that NSC-34 cells contain
on average approximately 213,000 molecules of HuD protein
and 109,000 molecules of Y3 RNA (see STAR Methods; Fig-
ure 4C). If the two HuD binding sites on Y3 were occupied by
different HuD molecules, this estimated ratio (1.95) would sug-
gest that Y3 might be able to sequester much or all of the HuD
population in standard NSC-34 culture conditions.
To quantitatively characterize the HuD/Y3 interaction, we
applied a luminescence proximity assay optimized for protein/
RNA interactions (D’Agostino et al., 2013). Biotinylated RNA
probes, representing Y3, Y3 lacking the conserved HuD binding
site (Y3-deleted) or a strong canonical 27 nt AU-rich sequence
element (ARE), were incubated with the recombinant HuD pro-
tein. Saturation binding experiments demonstrated a stronger
affinity for the Y3 RNA (Kd of 2.1 nM) as compared with the
ARE RNA (Kd of 5.9 nM), with no appreciable binding of Y3-
deleted (Figure 4D, upper panel). We confirmed these in vitro(D) Upper panel: saturation binding curves of recombinant HuD protein as functio
regression analysis. Three independent experiments were performed. Lower pan
cells expressing HuD protein. Two independent experiments were performed at
(E) HuD was induced in NSC-34 cells. Lysates were prepared and RNA pull-down
RNAs included in the extract (73 molar excess).
(F) RIP assay of HuD binding to Eef1a1, Eif4a2, and Ncam1 mRNAs after Y3 sile
In (D) and (F), data are represented as mean ± SEM t test *p < 0.05 and ***p < 0.
See also Figure S4.data with lysates from NSC-34 cells transfected with the HuD
construct: HuD binding activity to the Y3 probe was enriched
of about 30% with respect to the ARE RNA probe (Figure 4D,
lower panel).
Due to both its high intracellular levels and its high binding af-
finity for HuD, Y3 might effectively compete with the HuD mRNA
targets, acting as a specific HuD molecular decoy. To test this
hypothesis, we evaluated whether Y3 could compete for HuD
binding with some of the HuD mRNA targets we had previously
validated. We selected two sequences from the 30 UTRs of the
target Eif4a1 and Eef1a1 mRNAs, containing HuD binding sites
identified by CRAC and matching the size of the Y3 RNA (Fig-
ure 4E). Next, we measured the competition for HuD binding be-
tween the selected sequences and Y3. As shown in Figure 4E,
while Y3-deleted is not able to compete for the HuD/Y3 interac-
tion, the two selected mRNA target sites are able to compete. To
confirm the action of Y3 in reducing HuD association with its
target mRNAs, HuD was immunoprecipitated from NSC-34 cells
with or without prior treatment with siRNAs directed against Y3,
and three HuD-associated mRNAs (Eef1a1, Eif4a2, and Ncam1)
were quantified. Cells depleted for Y3 showed increased co-pre-
cipitation with HuD for all the three targets (Figure 4F). We also
verified that Y3 silencing did not affect the mRNA abundance
of these targets (Figure S4B).
Finally, we tested whether HuD post-translational modifica-
tions such as methylation and phosphorylation could alter HuD
binding to Y3 or to the ARE RNA probe, but we were unable to
detect significant differences (Figures S4C and S4D).
Collectively, this body of results shows that the Y3 ncRNA se-
questers HuD intracellularly and competes efficiently for HuD
binding with its target mRNAs.
Y3 Counteracts the Translation Enhancement Activity
of HuD
To assess the functional consequence of HuD sequestration by
Y3, we tested whether Y3 modulates the translation enhance-
ment ability exerted by HuD, by depleting Y3 in NSC-34 cells
(Figure 5A). Measurement of the TE indicated increased ribo-
some engagement in active translation (Figure 5A), and this
was supported by increased de novo protein synthesis following
Y3 depletion (Figure 5B). These results indicate that Y3 acts as a
general repressor of translation in NSC-34 cells.
To determine the relation between HuD and Y3 in the modula-
tion of translation, we measured de novo protein synthesis after
the following treatments: (1) HuD silencing by siRNA, (2) Y3
depletion by shRNA expression, and (3) combined silencing of
HuD and Y3. Combined Y3 and HuD knockdown partially
restored the reduction in protein synthesis observed following
HuD knockdown alone (Figure 5C). These data indicate thatn of increasing amount of RNA probes. Kd values were obtained by non-linear
el: AlphaScreen assay using ARE and Y3 RNA probes with lysates of NSC-34
the hooking point with 50 nM of RNA probes.
s with biotinylated Y3 were conducted either without (none) or with competitor
ncing; data were normalized to Gapdh mRNA levels in each IP.
001.
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A B
D
E
F
C Figure 5. Y3 Modulates HuD Translation
Functions
(A) Global translation output by sucrose gradient
profiles upon Y3 silencing in NSC-34 cells.
(B) De novo protein synthesis by AHA labeling upon
Y3 silencing in NSC-34 cells.
(C) AHA labeling experiments in NSC-34 cells
depleted for Y3, for HuD, or for both, showing
antagonism between Y3 and HuD on protein
synthesis.
(D) Western blot of HuD targets (Eef1a1 and Eif4a2)
and negative controls (Eif4a3) in NSC-34 cells
transiently silenced for Y3. Experiments were per-
formed at least in triplicate.
(E) Western blot analysis of EEF1A1, EIF4A2, and
EIF4A3 levels in HEK293 cells transiently trans-
fected with Y3 plasmid, alone or in combination with
HuD vector. Experiments were performed at least in
triplicate.
(F) Quantification of Eef1a1 and Eif4a2 protein levels
in primarymotor neurons transfectedwith an shRNA
construct directed against Y3 (sh_Y3) or a control
vector (sh_Ctrl) (n = >20 cells/condition).
In (A)–(F), data are represented as mean ±SEM t test
*p < 0.05, **p < 0.01, and ***p < 0.001.
See also Figures S5 and S6.the impact of HuD silencing on translation is mitigated if HuD
sequestration by Y3 is also reduced, presumably due to an in-
crease in the available pool of HuD (Figure 5C). To prove that
the Y3 modulatory effect on global translation is mediated by
the altered expression of HuD targets, we depleted Y3 in NSC-
34 cells and assessed the protein levels of Eef1a1, Eif4a2 and
the negative control Eif4a3. We observed a significant increase
for both HuD targets, but not Eif4a3 (Figure 5D). We also tested
the proposed molecular competition between Y3 and HuD on
the translation of specific HuD targets by ectopic expression in
HEK293 cells (Figure 5E). Overexpression of Y3 was associated
with a specific decrease in the protein levels of Eef1a1 and
Eif4a2, whereas no change was observed for Eif4a3. Co-expres-
sion of HuD restored protein expression of Eef1a1 and Eif4a2 to
control levels.
To confirm that these effects are due to the HuD/Y3 interac-
tion, we co-transfected HEK293 cells with HuD and wild-type
Y3 RNA or Y3-deleted RNA. While overexpression of HuD com-
binedwith the Y3-deleted RNA leads to an increase of the Eef1a1
and Eif4a2 targets, the effect is reduced upon HuD overexpres-
sion together with the wild-type Y3 (Figure S5B). We further
confirmed the ability of Y3 to prevent the translation of HuD264 Molecular Cell 71, 256–270, July 19, 2018target mRNAs using the human ovarian
cancer cell line ES2. We took advantage
of the fact that the interaction of the Y
RNA with their major binding protein, the
Ro60 autoantigen, is needed to avoid Y
RNA degradation (Xue et al., 2003). We
knocked out Ro60 by CRISPR/Cas9-
based genome editing, obtaining two
different Ro60-depleted cell clones. These
clones had, as expected, much less Y3RNA. Next, we rescued Ro60 expression in these clones. The
ability of HuD to enhance the expression of its targets was
conserved in ES2 cells, once more demonstrating that HuD
exerts translational enhancement in neural cells. When Y3 was
indirectly depleted by Ro60 knockout, the effect of HuD on
translation was enhanced, and again reduced upon Ro60 rescue
(Figure S5A).
We then verified if the functional interaction between HuD and
Y3 was also present in mouse primary embryonic motor neurons
(MNs). As previously reported (Fallini et al., 2011), HuD displays a
distinctive granular pattern of localization in MNs (Figures S6A
and S6B). Notably, primary MNs have high levels of endogenous
Y3, mainly localized to the axonal compartment (Figures S6C
and S6D). To test the effect of Y3 depletion on HuD targets,
we performed transfection with either an shRNA vector targeting
Y3 (shY3) or the empty control. We preliminarily tested the
silencing efficiency of the shY3 vector (Figure S6E). Compared
to control cells, shY3-treated MNs showed a significant increase
in Eef1a1 and Eif4a2 protein levels, recapitulating the functional
data obtained in NSC-34 cells (Figures 5F and S6F).
Collectively, these results show that Y3 counteracts the activ-
ity of HuD as a translation enhancer.
BA
C
Figure 6. Y3 Reduces the Association with Poly-
somes of HuD and HuD mRNA Targets
(A) Example of sucrose gradient absorbance profile of
NSC-34 cells treated with the scramble for siY3 (control
cells, upper panel). The first peak contains free cytosolic
light components (RNPs); the following peaks include
the ribosomal subunits (40S and 60S) and not translating
monosomes (80S). The peaks sedimenting at higher
sucrose concentrations represent polysomes. In the
lower panels, the co-sedimentation profiles of HuD
(at short and long exposure time, HuDs and HuDl,
respectively), RPL26 and RPS6 are shown under the
corresponding sucrose gradient fractions for both the
control (scramble, upper panels) and siY3 (lower
panels).
(B) Semiquantitative analysis of HuD, RPL26, and RPS6
relative protein levels along the sucrose gradient frac-
tions of control (gray lines) and siY3 (green lines) are
shown as the mean values obtained from three inde-
pendent experiments (n = 3).
(C) Semiquantitative analysis of Eif4a2, Eif4a3, 18S, and
Gapdh relative transcript levels along the sucrose
gradient fractions of control (gray lines) and Y3-depleted
(green lines) cells are shown as the mean values ob-
tained from three independent experiments (n = 3).
Data are represented as mean ± SEM t test *p < 0.05.
See also Figure S7.Y3 Sequesters HuD from the Polysomal Compartment
HuD can dynamically associate with polysomes (Bolognani
et al., 2004). To determine whether Y3 can modulate HuD
engagement on polysomes, we produced a co-sedimentation
profile of HuD along an entire sucrose gradient in NSC-34 cells
treated or not with Y3 siRNAs (Figure 6A). We found that HuD
significantly moves from the subpolysomal RNP compartment
to the polysomal one upon Y3 depletion (Figures 6A and 6B).
Y3 silencing does not instead affect the localization of the ribo-
somal proteins RPS6 and RPL26, used as negative controls (Fig-
ures 6A and 6B). Moreover, we excluded the possibility that the
enhanced association of HuD with polysomes was due to HuD
increased expression after Y3 silencing, since HuD and Y3 do
not mutually influence their abundance (Figures S7A–S7D). To
corroborate these results at the level of single HuD target tran-
scripts, we also monitored the changes in the localization of an
HuD target mRNA along the sucrose gradient upon Y3 depletion.
We chose Eif4a2 because it is one of the transcripts more heavily
modulated by HuD and particularly affected by Y3 competition
(Figure 6C), and because it is also themajor form of eIF4A in neu-
rons according to human expression databases and literature
(Hornburg et al., 2014). Upon Y3 depletion, we observed a rele-
vant increase in the Eif4a2 mRNA polysomal localization (Fig-
ure 6C, top left panel), consistent with the increased polysomal
localization of the HuD protein. Y3 silencing instead has minoror no effects on the localization of the Eif4a3,
18S, and Gapdh RNAs, used as negative con-
trols (Figure 6C).
These evidences, in combination with the
specific localization of Y3 within the cytosolic
RNP compartment and its absence from poly-somes (Figure S7E), strongly support a role for Y3 in seques-
tering HuD away from polysomes and from its target mRNAs,
preventing their translation.
Y3 Blocks the Function of HuD in Neuronal
Differentiation
Given the established role of HuD in promoting neuronal differ-
entiation during mammalian development, it seemed possible
that a developmentally regulated switch in the HuD/Y3 ratio
might control HuD availability for activity on mRNA targets,
thus boosting neuronal differentiation in a specific temporal
window. We analyzed changes in HuD and Y3 levels and ratio
during neuronal development by converting mouse embryonic
stem cells (mESCs) into neurons (Ying et al., 2003). We
measured HuD and Y3 levels at three different stages of the
differentiation procedure: mESC (D0), neural progenitors
(D7), and early neurons (D10). We observed a progressive in-
crease in levels of both Y3 and HuD during this process, but
with different kinetics (Figure 7A). Y3 showed a substantial in-
crease at the neural progenitor stage (2.5-fold at D7 relative to
D0) but then showed only a modest further increase (3-fold at
D10 relative to D0). In contrast, HuD exhibited a 5-fold in-
crease at the neural progenitor stage (D7) and a 10-fold in-
crease at the early neuron stage (D10). These results predict
that a strong reduction in HuD sequestration by Y3 at theMolecular Cell 71, 256–270, July 19, 2018 265
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Figure 7. Y3 Counteracts HuD-Induced Neurogenesis
(A) Differentiating ESCs cultures assayed for Y3 and HuD expression levels by Northern blot and western blot, respectively. Cultures were immunostained for
stage-specific markers: Oct4 (ESCs; red), Nestin (NPCs; red), and beta3-tubulin (early neurons; red); the scale bar corresponds to 75 mm. Relative quantification
of Y3 and HuD levels are shown (right).
(B) Differentiated NSC-34 cells (control or silenced for Y3) immunostained with anti-tubulin antibody (yellow) to detect neurites (left panel); GFP (green) identified
transfected cells subjected to high content analysis; the scale bar corresponds to 100 mm. Multiple parameters were analyzed using Operetta HCS device
(right panel).
(C) Differentiation assay in control Y3 silenced cells, Y3 silenced cells transfected with wild-type HuD or with mutant HuD. A schematic representation of HuD
constructs used in the experiment is provided.
(D) PC12 cells were co-transfected with HA-tagged HuD and mock or Y3 WT or Y3 ‘‘deleted’’ vectors. Co-transfected cells were immunostained with anti-HA
antibody, and the neurites were stained for tubulin.
In (A)–(D), data are represented as mean ± SEM t test *p < 0.05, **p < 0.01 and ***p < 0.001.neurogenic stage in vivo allows HuD to progressively drive
neuronal differentiation.
To directly test for a negative role for Y3 in neuronal differenti-
ation, we induced shY3 expression under differentiation condi-266 Molecular Cell 71, 256–270, July 19, 2018tions in NSC-34 cells. Y3 depletion significantly increased
neurite outgrowth in comparison to control cells (Figure 7B). To
demonstrate that this effect is specifically mediated by the
HuD/Y3 interaction, we first transfected NSC-34 cells with either
the wild-type HuD construct or the mutated version unable to
bind the Y3 RNA, after Y3 silencing and in differentiation condi-
tions. As shown in Figure 7C, wild-type HuD enhanced neuronal
differentiation in Y3-depleted cells, while mutant HuD lost this
function. To further support this finding, we co-transfected the
HuD vector with either wild-type Y3 or Y3-deleted vectors into
PC12 cells upon nerve growth factor (NGF) stimulation. Overex-
pression of wild-type Y3 resulted in a reduced neurite extension
in HuD transfected cells, while Y3-deleted, incapable of binding
HuD, had no effect (Figure 7D).
These results show that Y3 effectively counteracts HuD-in-
duced neuronal differentiation, and the increase of the HuD/Y3
ratio is a proposed way to trigger this program during
differentiation.
DISCUSSION
The crucial role of HuD in motor neuron plasticity and axon
regeneration (Akamatsu et al., 2005; Anderson et al., 2003; De-
scheˆnes-Furry et al., 2007) prompted us to set-up a method
providing a nucleotide-resolution map of HuD binding in motor
neuron-like cells. Our CRAC analysis showed that HuD is preva-
lently a 30 UTR binding protein (92% of binding sites) in the cod-
ing transcriptome (Figure 2B). Functional analysis of the HuD
interactome revealed, together with the strong neuronal differen-
tiation signature, an unexpected functional enrichment related to
translation. HuD resulted to bind up to 80 mRNAs of genes en-
coding for core components of the translational machinery (Fig-
ure 2A). The only available evidence of an action of HuD on global
translation comes from (Fukao et al., 2009), demonstrating the
binding of HuD to eIF4A1, which results in translation stimulation
of a reporter luciferase mRNA in HeLa extracts. Interestingly, in
their study the presence of the HuD binding site on the reporter
construct does not influence translational stimulation, suggest-
ing that indirect effects could be involved. We show for the first
time a strong stimulation of HuD on global translation in motor
neuron cells, assessed by increase in polysome formation and
de novo protein synthesis (Figures 2C–2E). This global transla-
tion enhancement could be at least partially mediated by the
direct effect of HuD on the elongation factors Eef1a1 and initia-
tion factors Eif4a1 and Eif4a2 (Figure 2H). Increased availability
of the helicase proteins and the induced HuD overexpression
could favor the formation of more HuD/eIF4A complexes (Fukao
et al., 2009, 2014), generating a positive feedback loop.
To our knowledge, such an extent of translational stimulation
in mammalian cells is only possible by the engagement of the
mTORC1 pathway, which mainly targets TOP and TOP-like
mRNAs (Hsieh et al., 2012; Meyuhas and Kahan, 2015; Thoreen
et al., 2012). Therefore, we checked the degree of coincidence
between mTOR responsive genes and HuD targets, clearly
demonstrating the high overlap among these lists (Figure 2G).
The mTORC1 pathway assures neuronal activity by promoting
differentiation and synaptogenesis. Similarly to the HuD-induced
phenotype in neurons (Figures S3C–S3E), the control of protein
synthesis through mTORC1 is also essential for axonogenesis
and dendritogenesis (Takei and Nawa, 2014). Therefore, we
wondered if the newly found HuD control of global translation
could act through stimulation of the mTORC1 pathway itself orinstead follow an independent route. The multiple experiments
we performed to resolve this issue (Figures 3A–3E) consistently
favored the second possibility, showing that suppression of the
mTORC1 translational burst can be rescued by HuD overexpres-
sion. Moreover, mRNAs respond to HuD with increased transla-
tion irrespective of the sequence at the 50 end. We believe that
this is the first demonstrated control of mTORC1-responsive
mRNAs spatially segregated from the mRNA 50 end. Indeed,
while very recent evidences have indicated that the translation
of TOP mRNAs is regulated to their 50 terminal through the
competitive binding between eIF4F, controlled by mTORC1 via
4E-BP proteins, and LARP1 (Philippe et al., 2018), we found
that HuD exerts its function through the binding of the TOP or
TOP-like mRNAs at the 30 UTR.
These results can be interpreted in terms of a synthetic inter-
action in motor neurons between the mTORC1 pathway and
HuD. We could hypothesize the existence of two independent
and redundant triggers of the translational machinery, targeting
two spatially segregated portions of the same mRNAs through
a fail-safe mechanism to assure the correct translational output
in highly polarized cells.
A second unexpected finding from our collection of HuD RNA
interactions is the specific and extensive association with the
Y3 RNA. Y RNAs are a conserved family of abundant small
non-coding RNAs (ncRNA), 100 nt long on average. Although
Y RNAs have been known for more than three decades, their
cellular functions in vertebrates remain elusive. Using a pan-
nELAV antiserum for CLIP analysis in human brain tissue,
Scheckel et al. (2016) recently reported the first evidence of
nELAV binding with 320 different Y sequences. So many
different interactors are likely due to the existence of 1,000 Y
retropseudogenes in the human genome (Perreault et al.,
2005). The cumulative Y/nELAV binding increased in Alz-
heimer’s disease brains and in UV-stressed neuroblastoma
cells (Scheckel et al., 2016). Our data in murine motor
neuron-like cells and with the specific nELAV HuD are instead
in favor of a very specific interaction with the Y3 RNA, fitting
the sequence consensus we found for HuD binding (Figures
4A and 4B). This high selectivity could have been favored
also by the existence in the mouse genome of only 60 Y retro-
pseudogenes, diverged in sequence from the two canonical
Y RNA genes (Perreault et al., 2007).
Surprisingly, the extent of association between HuD and Y3 in
our culture conditions is higher than the cumulative association
of the other 1,304 coding and 130 non-coding RNAs. Consid-
ering our estimation of the number of HuD and Y3 molecules
per cell (Figure 4C), in our conditions the majority of the ex-
pressed Y3 RNA could be associated to HuD. This is also sup-
ported by the higher affinity of HuD for Y3 with respect to a
strong, ARE-containing HuD binding RNA (Figure 4D). This evi-
dence is instrumental to the hypothesis that Y3 could efficiently
modulate HuD in its function as translational enhancer. The sub-
sequent set of experiments convinced us that Y3 negatively
affects HuD translational activity by efficiently sequestering it
from the translational compartment. In fact, Y3 is completely
absent from polysomes and localizes within the cytosolic
RNP compartment (Figure S7E). Consistently, Y3 silencing
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(Figures 4E and 4F) and increased the polysomal localization of
HuD (Figures 6A and 6B). On the functional side, Y3 depletion
increased HuD ability to boost translation and effectively
rescued HuD depletion (Figures 5A–C5). Similarly, HuD rescued
transcript-specific translation when overexpressed in combina-
tion with Y3 (Figures 5E and S5).
Finally, we observed a variation of HuD/Y3 level ratio during
neural mouse embryo stem cells differentiation (Figures 7A and
7B), and we demonstrated that neuronal differentiation can be
specifically modulated by the HuD-Y3 interaction (Figures 7C
and 7D). We therefore suggest that a developmentally regulated
switch in the HuD/Y3 ratio in vivo may induce release of active
HuD, thus boosting neuronal differentiation in a specific temporal
window. Interestingly, we also report a localization enrichment of
Y3 in primary motor neuron processes, mainly in the axons (Fig-
ure S6). HuD has been described to localize in axons and
dendrites and to actively associate with polysomes upon
depolarization (Tiruchinapalli et al., 2008). Therefore, the forma-
tion of a HuD/Y3 RNP could contribute to HuD silencing during
neuritic transport, triggering translation in neuron microdomains
following specific stimuli.
Our description of an efficient decoy activity on HuD function
by Y3 suggests a new role for the Y ncRNAs, which could extend
to other RBPs binding the loop region. The concept of competing
endogenous RNAs (Tay et al., 2014) is well established, and ap-
plies mostly to microRNAs sequestered from target mRNAs.
Functional sequestration of RBPs has been described for
some lncRNAs such as cyrano, which sequesters the HuD pa-
ralog HuR (Kim et al., 2016), previously shown by us to associate
to Y3 (Ko¨hn et al., 2015). Functions of the ELAV RBPs could
therefore be controlled by an extensive network of small and
long ncRNAs in different cell types.
In conclusion, our work introduces a novel key function for
HuD which could be exploited for therapeutic purposes. Limiting
to motor neuron diseases, in SMA mice increased mTORC1
signaling by downregulation of its negative controller PTEN
(Ning et al., 2010) rescues axonal defects and improves survival.
For these reasons, attempts aimed at stimulating the mTORC1
pathway could have therapeutic potential for degenerating
motor neurons. We report here a new activity of HuD as an
mTORC1-independent global translational enhancer. This activ-
ity offers a window of therapeutic opportunity, which becomes
even more interesting when considering the high modulation of
HuD function exerted by the Y3 ncRNA.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-MAP2 Sigma Aldrich Catalog number M4403;
RRID: AB_477193
Rabbit polyclonal anti-TAU Synaptic System Catalog number 314 002;
RRID: AB_993042
Mouse monoclonal anti-SMI32 Abcam Catalog number ab7795;
RRID: AB_306084
Rabbit polyclonal anti-MNX1 (HB9) Merck Millipore Catalog number ABN174;
RRID: AB_2732012
Mouse monoclonal anti-HUD (E-1) Santa Cruz Biotechnology Catalog number sc-28299;
RRID: AB_627765
Mouse monoclonal Anti-b-Tubulin III Sigma Aldrich Catalog number T8578;
RRID: AB_1841228
Mouse monoclonal anti-eEF1A1, clone CBP-KK1 Merck Millipore Catalog number 05-235;
RRID: AB_309663
Rabbit polyclonal anti eIF4A2 Abcam Catalog number ab31218;
RRID: AB_732123
Rabbit polyclonal anti-PABP Abcam Catalog number ab21060;
RRID: AB_777008
Mouse monoclonal anti-DCP1A Abcam Catalog number ab57654;
RRID: AB_942144
Mouse monoclonal Anti-TIA-1 Santa Cruz Biotechnology Catalog number sc-166247;
RRID: AB_2201545
Mouse monoclonal anti-Oct4 (C-10) Santa Cruz Biotechnology Catalog number sc-5279;
RRID: AB_628051
Mouse monoclonal anti-Nestin, (clone rat-401) Merck Millipore Catalog number MAB353;
RRID: AB_94911
Mouse monoclonal anti-b-Tubulin III Promega Catalog number G712A
Goat anti-Rabbit IgG (H+L) polyclonal, Cross-Adsorbed
Secondary Antibody, Alexa Fluor 488
Thermo Fisher Scientific Catalog number A-11008;
RRID: AB_143165
Goat anti-Rabbit IgG (H+L) polyclonal, Cross-Adsorbed
Secondary Antibody, Alexa Fluor 594
Thermo Fisher Scientific Catalog number A-11012;
RRID: AB_2534079
F(ab)2-Goat anti-Mouse IgG (H+L) polyclonal, Cross-
Adsorbed Secondary Antibody, Alexa Fluor 488
Thermo Fisher Scientific Catalog number A-11017;
RRID: AB_2534084
F(ab)2-Goat anti-Mouse IgG (H+L) polyclonal, Cross-
Adsorbed Secondary Antibody, Alexa Fluor 594
Thermo Fisher Scientific Catalog number A-11020;
RRID: AB_2534087
Donkey anti-Rabbit IgG (H+L) polyclonal, Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 488
Thermo Fisher Scientific Catalog number A-21206;
RRID: AB_2535792
Donkey anti-Goat IgG (H+L) polyclonal, preadsorbed
Secondary Antibody, Alexa Fluor 594
Abcam Catalog number ab150136
mouse monoclonal anti-b-tubulin (3F3-G2) Santa Cruz Biotechnology Catalog number sc-53140;
RRID: AB_793543
Rabbit polyclonal anti-HA Bethyl laboratories Catalog number A190-108A;
RRID: AB_67465
Rabbit polyclonal anti-eIF4A1 Abcam Catalog number ab31217;
RRID: AB_732122
Rabbit anti-eIF4A3 Home made by Prof.
Macchi’s Lab
Rabbit polyclonal anti-eEF1A1 Sigma Aldrich Catalog number SAB2108050
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Rabbit polyclonal anti-PABPC1 Sigma Aldrich Catalog number SAB2101708;
RRID: AB_10604467
Rabbit polyclonal anti-Rpl26 Abcam Catalog number ab59567;
RRID: AB_945306
Rabbit monoclonal anti-S6 Cell Signaling Technology Catalog number 2217;
RRID: AB_331355
Bacterial and Virus Strains
XL1 Blue Stratagene Catalog number 200249
DH5alpha This study N/A
Chemicals, Peptides, and Recombinant Proteins
Doxycycline Sigma-Aldrich Catalog number A3656
Torin1 EMD MILLIPORE Catalog number 475991
Sodium arsenite solution EMD MILLIPORE Catalog number 1.06277
Cycloheximide (CHX) Sigma-Aldrich Catalog number C7698
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich Catalog number P8139
Dimethyl Sulfoxide (DMSO) Fisher Scientific Catalog number BP2311
NGF Sigma-Aldrich Catalog number N6009
GDNF Peprotec Catalog number 450-44-10
CNTF Peprotec Catalog number 450-13-10
BDNF Peprotec Catalog number 450-02-10
Collagen type IV Sigma-Aldrich Catalog number C5533
Laminin Mouse Protein, Natural Thermo Fisher Scientific Catalog number 23017015
Lectin Sigma L9640 Sigma-Aldrich Catalog number L9640
Poly-DL-ornithine hydrobromide Sigma-Aldrich Catalog number P8638
Recombinant His-HuD protein This study N/A
Critical Commercial Assays
Pierce Anti-HA Magnetic Beads Thermo Fisher Scientific Catalog number 88836
IBA Lifesciences Ni-NTA Superflow Fisher Scientific Catalog number 2-3206-025
Pierce Anti-HA Agarose Beads Thermo Fisher Scientific Catalog number 26181
Streptavidin MyOne T1 beads Thermo Fisher Scientific Catalog number 65601
ECL Prime Western Blotting System GE Healthcare Sigma-Aldrich Catalog number GERPN2232
Bradford Reagent Sigma-Aldrich Catalog number B6916
Lipofectamine RNAiMAX Reagent Thermo Fisher Scientific Catalog number 13778030
Lipofectamine 2000 Thermo Fisher Scientific Catalog number 11668027
Dual-Glo Luciferase Assay System Promega Catalog number E2920
Retinoic acid Sigma-Aldrich Catalog number R2625
Click-iT AHA Alexa Fluor Protein Synthesis HCS Assay Thermo Fisher Scientific Catalog number C10289
Hoechst 33342 Thermo Fisher Scientific Catalog number 62249
Starting Kit: Magnetic Plate + NeuroMag 200 mL OZ Bioscience Catalog number KC30800
AlphaScreen HA (Hemagglutinin) Detection Kit PerkinElmer Catalog number 6760612C
TruSeq Stranded mRNA Library Prep Illumina Catalog number 20020594
TruSeq Targeted RNA Custom Panel Kit Illumina Catalog number RT-101-1001
QuantSeq 30 mRNA-Seq Library Prep Kit REV Lexogen Catalog number 016.24
iScriptcDNA synthesis kit Biorad Catalog number 1708891
KAPA SYBR FAST Universal 2X qPCR Master Mix Kapa Biosystems Catalog number KK4601 –
07959389001
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Deposited Data
Raw Imaging files This study, Mendeley Data https://doi.org/10.17632/p34w7w78hy.1
Sequence files This study, GEO GSE115490 https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE115490
Reference mouse genome annotation Gencode M6 Gencode https://www.gencodegenes.org/
mouse_releases/6.html
Experimental Models: Cell Lines
H. sapiens: HEK293T Quattrone A. Lab (CIBIO) RRID: CVCL_0045
M. musculus: NSC34 Tebu-bio RRID: CVCL_D356
M. musculus: NSC-34-Trex This study N/A
M. musculus: NSC-34-HuD This study N/A
M. musculus: NSC-34-shHuD This study N/A
R. norvegicus: PC12 Quattrone A.Lab (CIBIO) RRID: CVCL_0481
M. musculus: 46C ES Conti L. Lab (CIBIO) RRID: CVCL_Y482
H. sapiens: CRISPR Knockout Ro60 ES2, Clone 1 Huettelmaier S. Lab N/A
H. sapiens: CRISPR Knockout Ro60 ES2, Clone 1 Huettelmaier S. Lab N/A
Experimental Models: Organisms/Strains
C57BL/6J mice The Jackson Laboratory Catalog number 000664;
RRID: IMSR_JAX:000664
Oligonucleotides
See Table S2 for complete list of primers used for qPCR
analysis and barcodes used for CRAC
This study N/A
Y3 siRNA AACUAAUUGAUCACAACCAGU Ko¨hn et al., 2015 N/A
Ctrl siRNA AGGUAGUGUAAUCGCCUUG This study N/A
HuD siRNA Santa Cruz Biotechnology Catalog number sc-37836
Control siRNA Santa Cruz Biotechnology Catalog number sc-37007
Y1 Northern Blot probe, ATAACTCACTACCTTCGGA
CCAGCC
Ko¨hn et al., 2015 N/A
Y3 Northern Blot probe, CTGTAACTGGTTGTGATCA
ATTAGT
Ko¨hn et al., 2015 N/A
Biotinylated ARE RNA AUUAUUUAUUAUUUAUUUA
UUAUUUA
This study N/A
Biotinylated mY1 RNA, GGCTGGTCCGAAGGTAGTG
AGTTATCTCAATTGATTGTTCACAGTCAGTTACAGAT
TGAACTCCTGTTCTACACTTTCCCCCCTTCTCACTA
CTGCACTTGACTAGTCTTTT
Ko¨hn et al., 2015 N/A
Biotinylated mY3 RNA, GGTTGGTCCGAGAGTAGTG
GTGTTTACAACTAATTGATCACAACCAGTTACAGAT
TTCTTTGTTCCTTCTCCGCTCCCACTGCTTCACTT
GACCAGCCTTTT
Ko¨hn et al., 2015 N/A
Biotinylated hY4 RNA, GGCTGGTCCGATGGTAGTG
GGTTATCAGAACTTATTAACATTAGTGTCACTAAAG
TTGGTATACAACCCCCCACTGCTAAATTTGACTG
GCTTTTT
Ko¨hn et al., 2015 N/A
Recombinant DNA
pCMV6-AN-His-HA Origene Catalog number PS100017
pCMV6-His-HA-HuD This study N/A
pCMV6-His-HA-HuD (R248K) This study N/A
pLenti CMV/TO His-HA-HuD This study N/A
pGEM-T-Y3wt Ko¨hn et al., 2015 N/A
pGEM-T-Y3mut (mutant lacking the HuD binding motif) This study N/A
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pT7-HuD-WT Fukao et al., 2009 N/A
pT7-HuD-MUT(mutant lacking any RNA-binding activity Fukao et al., 2009 N/A
pT7-HuD-14-302 Fukao et al., 2009 N/A
pT7-HuD-216-385 Fukao et al., 2009 N/A
pIS1-Eef25UTR-TOPwt Thoreen et al., 2012, A Addgene Plasmid, Catalog
number 38235
pIS1-Eef25UTR-TOPmut Thoreen et al., 2012, A Addgene Plasmid, Catalog
number 38236
pIS1-Eef25UTR-TOPwt-30UTR Eef1a1 This study N/A
pIS1-Eef25UTR-TOPmut-30UTR Eif4a3 This study N/A
pIS1-Eef25UTR-TOPwt-30UTR Eef1a1 This study N/A
pIS1-Eef25UTR-TOPmut-30UTR Eif4a3 This study N/A
pHuD-GFP vector Fallini et al., 2011 N/A
pshHuD This study N/A
pshY3 This study N/A
pCDNA-SBP-HuD This study N/A
Software and Algorithms
Prism GraphPad, v5 https://www.graphpad.com/
Harmony software version 4.1 PerkinElmer N/A
ImageJ software version 1.43u NIH https://imagej.nih.gov/ij/
Microscope Software Zen 2012 (Blue Edition) Zeiss https://www.zeiss.com/
Adobe Photoshop 7.0 Adobe Systems Incorporated https://www.adobe.com/products/
photoshop.html
hyb https://github.com/gkudla/hyb N/A
Tophat (version 2.0.14) http://ccb.jhu.edu/software/
tophat/index.shtml
N/A
R https://www.r-project.org/ N/A
STAR (version 2.5.3a) https://github.com/alexdobin/
STAR
N/A
Bioconductor https://www.bioconductor.org/ N/A
enrichR http://amp.pharm.mssm.edu/
Enrichr/
N/A
Other
Stratalinker UV crosslinker 1800 Stratagene N/A
UA-6 UV/VIS detector Teledyne Isco N/A
High Content Screening System Operetta PerkinElmer N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alessan-
dro Quattrone (alessandro.quattrone@unitn.it).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
NSC-34 is a murine hybrid cell line produced by fusion of mouse neuroblastoma cells with motoneuron-enriched embryonic spinal
cord cells. NSC-34 cells were grown in DMEMmediumwith 10%FBS, 100 U/ml penicillin streptomycin and 0.01mML-glutamine (all
medium ingredients were obtained from GIBCO). Human embryonic kidney HEK293 and human carcinoma (ES-2) cell lines were
cultured in the same media and conditions. PC12 cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum and 5% horse serum, 100 U/ml penicillin streptomycin and 0.01 mM L-glutamine.e4 Molecular Cell 71, 256–270.e1–e10, July 19, 2018
Mouse 46C ESCs (Ying et al., 2003) were maintained in GlasgowMinimal Essential medium (Sigma) supplemented with 10% heat-
inactivated fetal bovine serum (EuroClone), 100 mM non-essential amino acids (Thermo Fisher), 1 mM sodium pyruvate (Thermo
Fisher), 2 mM L-glutamine (Thermo Fisher), 100 U ml1 penicillin (EuroClone), 100 mg ml1 streptomycin (EuroClone), 1 mM b-mer-
captoethanol (Thermo Fisher) and 1,000 U ml1 murine leukemia inhibitor factor (ESGRO, Millipore) in gelatinized tissue culture
flasks. Cells were passaged every 2-3 days after dissociation with 0.05% trypsin-EDTA (Thermo Fisher).
Primary motor neurons were isolated from embryonic mouse spinal cord. Lumbar spinal cord tissues were carefully dissected
under microscopy, dissociated in trypsin and transfer in a lectin-coated plate. Lectin has been shown to specifically bind to
p75NTR helping motorneurons enrichment. After washing, the cells were resuspended in neurobasal medium supplemented with
1% GlutaMAX, 2% B27 supplement, 5% horse serum and neurotrophic factors (BDNF, GDNF and CTNF at 10 ng/ml), and plated
on PORN-H/laminin-coated plates. These mice-related activities were authorized by the Institutional Review Board of the University
of Trento.
All cultures were grown at 37C in a 5% CO2 incubator.
METHOD DETAILS
Plasmids
To generate pCMV6-HIS-HA-HuD plasmid, the cDNA sequence of human HuD was amplified from SK-N-BE(2) neuroblastoma cell
line using the following primers containing Sgf I and Mlu I restriction sites:
Fw HuD 50-GAGGCGATCGCCGAGCCTCAGGTGTCAAATGG-30
Rv HuD 50-GCGACGCGTTCAGGACTTGTGGGCTTTGTTGG-30
The amplified fragment was digested with Sgfi andMluI enzymes and cloned into the same sites of pCMV6-AN-His-HA vector, that
contains an amino-terminal polyhistidine (His) tag and an hemagglutinin (HA) epitope (PS100017, OriGene, Rockville, MD). Site-
directed mutagenesis was used to create an ‘‘unmethylatable’’ form of HuD. Briefly, pHA-HuD vector was used as PCR-template
to generate a mutant of HuD, replacing the arginine at position 248 with a lysine (R248K). The primers containing the mutation are
listed as follows:
R248K: (F) 50-CCACCAGGCTCAGAAGTTCAGGCTGGACA-30 and
(R) 50-TGTCCAGCCTGAACTTCTGAGCCTGGTGG-30;
To generate a lentiviral vector expressing tagged HuD, His-Ha-HuD was excised from pCMV6-AN-His-HA using BamHI and XhoI
enzymes and subcloned in the same sites of pENTR-DsRed2 N1 (CMB1) vector. This plasmid was then recombined into pLenti
CMV/TO Puro DEST (670-1, Addgene) destination vector using the Gateway system (Life technologies).
For HuD knockdown, the following oligonucleotides were synthesized and annealed:
50-GATCCCGCATCCTGGTTGATCAAGTGTGTGCTGTCCACTTGATCAACCAGGATGCTTTTTGGAAA-30;
50-AGCTTTTCCAAAAAGCATCCTGGTTGATCAAGTGGACAGCACACACTTGATCAACCAGGATGCGG-30.
Annealed fragments were ligated into the BglII and HindIII sites of pENTR/pSUPER+ (Addgene 575-1) and transferred into pCMV-
GFP-DEST (Addgene 736-1), taking advantage of Gateway technology.
For knockdowns of Y3 by shRNAs, the following oligonucleotides were used:
50-GATCCCCAACtAAttGAtCACAACCAGtTTCAAGAGAACTGGTTGTGATCAATTAGTTTTTTC-30
50-TCGAGAAAAAACTAATTGATCACAACCAGTTCTCTTGAAaCTGGTTGTGaTCaaTTaGTTGGG-30. Annealed primers were
ligated into pSuperior-GFP (OligoEngine), which was cut with BglII/XhoI. The empty vector served as negative control.
For Y3 overexpression, a pGEM-T clone including the whole Y3 gene (Ko¨hn et al., 2015) was used. The sequence of Y3 mutant,
lacking the HuD binding motif (AUUUCUUUGUUCCUUCU), was derived from CRAC data analysis, synthesized and cloned into
pGEM-T vector.
To characterize Y3 binding with HuD, the following plasmids, kindly provided by Dr. Toshinobu Fujiwara, were used: pHuD-wt
expressing murine HuD wild-type (wt), HuD-MUT vector lacking any RNA-binding activity, the HuD-14-302 lacking the poly(A)-
binding domain RRM3 and theHuD-216-385 lacking the ARE-binding domain (RRM1 and RRM2).
The luciferase reporter vectors were generated by cloning the specific 30UTR sequences into pIS1-Eef25UTR-renilla vector (Addg-
ene 38235), that harbors a canonic TOP motif in 50UTR. Specifically, the 30UTR of Eef1a1, Eif4a1, Eif4a2, Eif4a3 and Rpl10 were
amplified from murine cDNA by using the following primers:
Eef1a1 Fw 50-GCACGGATATCATATTACCCCTAACACCTGC-30
Rv 50-GCACGTCTAGACAGATTTCTCATTAAACTTG-30;
Eif4a1 Fw 50-GCACGGATATCGGGGCTGTCCTGCGACCTGGCC-30
Rv 50-GCACGTCTAGAAGGCAGTTTCCAAGTAATTTTA-30;
Eif4a2 Fw 50-GCACGGATATCGGATGAGATAGTTTTGAATGC-30
Rv50-GCACGTCTAGACTTCATTAAGACATGTGCAAT-30;
Eif4a3 Fw 50-GCACGGATATCAGCTGGTGCTGGTGCACCGAG-30
Rv 50-GCACGTCTAGATCACAGGAAAATGTCCACGTT-30;
Rpl10a Fw 50-TTTTTGATATCCACGTGAAGATGACCGATGAT-30
Rv 50-TTTTTTCTAGAGAGTGGCAGCAGTGAGGTTTAT-30.Molecular Cell 71, 256–270.e1–e10, July 19, 2018 e5
The amplified 30UTRs were then digested with EcoRV and XbaI enzymes and cloned in the same sites of pIS1-Eef25UTR-renilla
vector. In addition, Eef1a1 30UTR and Eif4a3 30UTR were cloned into pIS1-Eef25UTR-TOPmut-renilla vector (Addgene 38236),
that contains a mutated TOP motif in 50UTR. All plasmids were sequence-verified.
Generation of Tetracycline (Tet) inducible cell lines
Tetracycline (Tet) inducible cell lines were generated as previously described (Sanna et al., 2015). Briefly, NSC-34 cells were primarily
transduced with the pLentiCMV_TetR_Blast vector (716-1, Addgene). To establish an inducible cell line overexpressing the human
HuD protein, NSC-34-Trex cells were infected with a lentiviral vector expressing His-HA tagged HuD. Alternatively, NSC-34-Trex
cells were stably transfected with pSUPERIOR.neo+GFP plasmid containing the short hairpin sequence for Y3 or the empty vector
as a negative control. In both cell lines, the inducible expression of the transgene (HuD or shRNA respectively) was induced by adding
2 mg/ml doxycycline (Clontech) to the culture medium.
Isolation of motor neuron compartments
Primarymotor neurons were isolated from embryonic mouse spinal cord and cultured as previously reported (Conrad et al., 2011). To
separate motor neuron axons from cell soma and dendrites, the use of coated filter insert (3.0 mm pores PET membrane) was adop-
ted. After 5 days, the different cellular compartments were rapidly collected by scraping the both sides of PET membranes and RNA
was extracted by Trizol (Life Technologies). To qualitatively analyze the separation of motor neuron axons from cell soma and den-
dritic tree, a small PET membrane piece was cut away, immersed in 4% PFA and processed for immunofluorescence.
Small interfering RNA (siRNAs) and cell transfections
For gene silencing of Y3, the following siRNA duplexes were used: AACUAAUUGAUCACAACCAGU for Y3 (Ko¨hn et al., 2015) and
AGGUAGUGUAAUCGCCUUG as non specific control (47% GC) (Eurofins Genomics); HuD was silenced by transfection of HuD
siRNA (sc-37836, Santa Cruz) or control siRNA (sc-37007) from Santa Cruz (Kang et al., 2014). Cells were transfected with
100 nM of the indicated siRNAs for 24h by using Lipofectamine RNAiMAX Reagent (Life technologies).
HEK293 cells were transiently transfected with His-HA HuD plasmid or the His-HA empty vector as control. The transfections were
performed using Lipofectamine 2000 (Life Technologies); 48h after transfections cells were harvested for the analysis.
For luciferase assay, HEK293 cells were transfected with His-HA HuD or His-HA empty vector (75ng). After 24 h, the cells were
transfected with both the different renilla luciferase reporter vectors (50 ng) and Firefly luciferase (5 ng) for the normalization. The lucif-
erase activity was measured after 24h using Dual-Glo Luciferase Assay System (Promega) following the manufacturer’s instructions.
Motor neurons (2 DIV) were transfected by magnetofection using NeuroMag (OZ Bioscience) according to the manufacturer’s pro-
tocol. At 5 DIV, neurons were fixed in 4% PFA and immunostained.
NSC-34 cell treatments
To inhibit mTORC1 pathway, NSC-34 cells were starved by serum depletion in DMEM medium without FBS for 8h or treated with
Torin1 (500nM) for 1h. After the incubation time, the cells were collected for the following analysis. For the induction of cytoplasmic
stress granules, NSC-34 cells were starved for 8h and then treated with 0.25mMof sodium arsenite (Sigma-Aldrich). After 45min, the
cells were fixed und subjected to immunofluorescence analysis.
Cell Differentiation
NSC-34 cells were seeded onto collagen coated (50 ug/mL) 96-well microplate. The normal medium was exchanged 24h after seed-
ing to differentiation medium containing 1:1 DMEM/F-12, 1% FBS, 1% modified Eagle’s medium nonessential amino acids (NEAA),
1% P/S, 5 mM retinoic acid for seven days. HuD overexpression or Y3 short hairpin were induced by 2 ug/mL doxycycline. The dif-
ferentiation medium was changed after three days. For PC12 cells, they were plated on collagen-coated plates and differentiated
with 100 ng/ml NGF in Dulbecco’s modified Eagle’s medium supplemented with 1% horse serum. After 24h, the cells were trans-
fected with HUD and Y3 vectors and maintained for 5 days in differentiation medium.
ESC neural conversion/neuronal differentiation procedure was performed as previously described (Ying et al., 2003). Briefly, ESCs
were dissociated and plated onto 0.1% gelatin-coated tissue culture plastic dishes at a density of 1 3 104 cells per cm2 in N2B27
medium. Mediumwas completely renewed every 2 days. N2B27mediumwas a 1:1 mixture composed of DMEM/F12 supplemented
with N2 and Neurobasal medium supplemented with B27 (Thermo Fisher). After day 9, cell culture medium was shifted to diff-N2B27
composed of a 1:4 mixture of DMEM/F12 supplemented with N2 and Neurobasal medium supplemented with B27 (Thermo Fisher).
Immunofluorescence microscopy
Immunofluorescence of both motor neurons, NSC-34 cells and differentiating ESCs, was performed with the same protocol. After
fixation in 4% PFA, cells were permeabilized in PBS + 0.1% Triton X-100 for 5 min and incubated in blocking solution (2% bovine
serum albumin, 2% fetal bovine serum, 0.2% gelatin in PBS) for 30 min at RT. Primary antibodies were incubated for 2 hours at
RT in blocking solution diluted 1:10 in PBS. The following primary antibodies were used: mouse anti-MAP2 1:300 (M4403, Sigma-
Aldrich), rabbit anti-Tau 1:300 (314 002, SynapticSystem), anti-SMI32 (200 KDa neurofilament) 1:300 (Ab7795, Abcam), rabbit
anti-MNX1 1:100 (ABN174, Millipore), mouse anti-HuD 1:200 (sc-28299, Santa Cruz), mouse anti-beta III Tubulin (T8578, Sigmae6 Molecular Cell 71, 256–270.e1–e10, July 19, 2018
Aldrich), mouse anti-eEF1A1 (05235, Millipore), rabbit anti-eIF4A2 (31218, Abcam), rabbit anti-PABP 1:500 (Ab21060, Abcam),
mouse anti-DCP1A 1:200 (Ab57654, Abcam), goat anti-TIA1 1:100 (sc-166247, Santa Cruz), mouse anti-Oct4 1:400 (sc-5279, Santa
Cruz), mouse anti Nestin 1:400 (MAB353, Merck-Millipore), mouse anti beta3-Tubulin 1:1000 (G712A, Promega). The following sec-
ondary antibodies, diluted 1:800, were used: goat anti-rabbit Alexa Fluor 488 (A11008, Thermo Fisher Scientific), goat anti-rabbit
Alexa Fluor 594 (A11012, Thermo Fisher Scientific), goat anti-mouse Alexa Fluor 488 (A11017, Thermo Fisher Scientific), goat
anti-mouse Alexa Fluor 594 (A11020, Thermo Fisher Scientific), donkey anti-rabbit Alexa Fluor 488 (A21206, Thermo Fisher Scien-
tific), donkey anti-goat Alexa Fluor 594 (Ab150136, Abcam). Nuclei were stained with DAPI. Images were acquired with Zeiss
Observer Z.1Microscope implemented with the Zeiss ApoTome device. The objective used for image acquisition was either PlanApo
oil immersion lens 63x/1.4 or EC Plan-Neofluor 20x/0.5. Pictures were acquired using AxioVision imaging software package (Zeiss)
and assembledwith Adobe Photoshop 7.0. Images were notmodified other than adjustments of levels, brightness andmagnification.
Neurite outgrowth analysis
NSC-34 cells were fixed after seven days of differentiation and stained with Hoechst and mouse anti-Tubulin antibody (1:800;
sc-53140, Santa Cruz). For HuD overexpressing cells, an additional immunostaining with a rabbit anti-HA antibody (1:600; A190-
108A, Bethyl Laboratories) was performed. The following secondary antibodies, diluted 1:800, were then used: goat anti-rabbit Alexa
Fluor 594 (A11012, Thermo Fisher Scientific), goat anti-mouse Alexa Fluor 488 (A11017, Thermo Fisher Scientific) and goat anti-
mouse Alexa Fluor 594 (A11020, Thermo Fisher Scientific).
Neurite outgrowth was then analyzed on tubulin positive cells by High Content Screening System Operetta (PerkinElmer). Briefly,
plates (96-well CellCarrier, PerkinElmer) were imaged and acquired in preselected fields with LWD 20x objective. For the feature
extraction, the images were analyzed by Harmony software version 4.1 (PerkinElmer). Based on the Hoechst dye cell nuclei were
identified. Starting from the cell body region, neurites were then detected in tubulin positive cells. The building block ‘‘Find Neurites’’
automatically calculated for each cell a set of neurite properties.
CRAC
The CRAC protocol was modified from the published one used in (Helwak et al., 2013). Trex-HuD NSC-34 and control Trex NSC-34
cells were seeded onto 150 mm plates (Nunc, Thermo Scientific). Cells were then induced for human HuD production with 10 mg/ml
Tetracycline. 24 h post induction growing cells were UV crosslinked on ice with l = 254 nm in Stratalinker 1800 (Stratagene). The cells
were lysed and treated with DNase (Promega M610A). Cell lysates were incubated with HA agarose beads (26181 Pierce). Ribonu-
cleoprotein complexes on HA beads were trimmed with 0.5 unit RNaseA+T1 mix (RNace-IT, Stratagene 400720-81) and HuD-RNA
complexes were eluted. The eluate was incubated with Ni-NTA Agarose (Ni-NTA Superflow 50% suspension IBA 2-3206-010). RNAs
bound to HuD were radiolabelled with 32P-g-ATP and 30 miRCat-33 linker ligation was performed. Then RNA ligase 1 and barcoded
50 linker were added and the reaction mixture HuD-RNA complexes were eluted by incubation with NuPage-Eluition buffer. Protein-
RNA complexes were resolved on a 4%–12% Bis-TrisNuPAGE gel (Life Technologies, NP0335) in NuPAGE SDS MOPS running
buffer (Life Technologies, NP0001) and transferred to nitrocellulose membrane (GE Healthcare, AmershamHybond ECL). Air-dried
membrane was exposed on film o.n. and the radioactive bands corresponding to the HuD complexes were cut out. RNA was ex-
tracted and reverse transcribed. cDNA was amplified and PCR products were precipitated, resuspended and separated on a
2.5% MetaPhoragarose (Lonza). After purification with Gel Extraction Kit with MinElute columns (QIAGEN) the samples were
sequenced on Illumina HiSeq 2000 platform.
Polysome profiling
Polysomal profiling was performed according to previously described protocols (Bernabo` et al., 2017). Briefly, the cells were treated
with cycloheximide and then lysed in 300 mL of cold lysis buffer. The lysate was centrifuged at 4C for 5min at 20.000 g to pellet cell
debris. The cytoplasmic lysates loaded on a linear 15%–50% [w/v] sucrose gradient and centrifuged in a SW41Ti rotor (Beckman) for
1 h 40 min at 180.000 g at 4C in a Beckman Optima Optima XPN-100 Ultracentrifuge. Fractions of 1 mL of volume, were then
collected monitoring the absorbance at 254 nm with the UA-6 UV/VIS detector (Teledyne Isco).
Extraction of total and polysomal RNA
Sucrose fractions corresponding to polysomes and total RNA were pooled together and the RNA was processed by acid phenol–
chloroform extraction. Alternatively, the mRNAs were isolated from single fractions along sucrose gradient as described in (Bernabo`
et al., 2017).
RT-qPCR analysis
The retrotranscription reaction was performed with 1 mg of polysomal or total RNA using the iScriptcDNA synthesis kit (Biorad) in
accordance with the manufacturer’s instructions. The obtained cDNA was used as template in aqPCR reaction with the KAPA
SYBR FAST qPCR (Kapa Biosystem) and specific primers as reported in Table S3. qPCR were run in three biological and three tech-
nical replicates. The relative expression was calculated with the delta delta Ct method. Gapdh and Als2 were used as reference
genes. The gene-specific Translation Efficiency (TE) was calculated as the ratio between the fold change at the polysomal level
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Library preparation for RNA-Seq and POL-Seq
Total and Polysomal RNA samples were converted to cDNA libraries according to the Illumina TruSeq Stranded mRNA Library Prep.
The sequencing was performed on Illumina HiSeq 2500 platform.
Library preparation for TruSeq Targeted RNA Expression
The library was prepared using TruSeq Targeted RNA Expression following the manufacturer’s instruction and the sequencing was
performed on the MiSeq Illumina platform.
RNP immunoprecipitation and RNA pulldown
The HuD ribonucleoproteincomplex was isolated as previously described (Sanna et al., 2015). Immunoprecipitated and input sam-
ples were resuspended in Trizol reagent (Life Technologies) and RNA extraction was performed following manufacturer’s
instructions.
RNA pulldowns were essentially performed as previously described (Ko¨hn et al., 2015). For synthesis of the RNA baits (Y1, Y3, Y4)
T7-Polymerase mediated in vitro transcription was used.
SBP Pulldown
To pull down HuD and HuD-fragments inserts were cloned into the pCDNA-SBP-Flag vector. After transfection into NSC-34, cells
were harvested after 48h. Cell pellets were lysed using BB (100 mMKCl, 10mM EDTA, 10 mM HEPES pH 7.4, 0.5% NP-40) and
the supernatant was incubated with Streptavidin MyOne T1 beads (Life Technologies). Beads were then washed three times with
BB and bound proteins were eluted by addition of BB+1% SDS and heating at 65C. Eluates were then separated for RNA and pro-
tein preparations. Input and pulldown RNAwas purified using Trizol (Sigma-Aldrich) and subjected to Northern Blot. Protein samples
were subjected to Western Blot.
Northern and western blot
Northern Blot was essentially performed as previously described (Ko¨hn et al., 2013, 2015).
For western blot analysis, NSC-34 and HEK293 cells were homogenized in RIPA lysis buffer (Sigma) following the manufacturer’s
instructions. The isolation of proteins along sucrose gradient were performed as described in (Bernabo` et al., 2017). Protein lysates
were resolved on SDS-PAGE and transferred to nitrocellulose membrane.
The following antibodies were used: mouse anti HuD (sc-28299, Santa Cruz), rabbit anti HA (A190-1081, Bethyl Laboratories), rab-
bit anti eIF4A1 (ab312-17, Abcam), rabbit anti-eIF4A2 (31218, Abcam), rabbit anti-eIF4A3 (homemade, generously provided from
Prof. Macchi’s lab), rabbit anti eEF1A1 (SAB2108050, Sigma), mouse anti Tubulin (sc-53140, Santa Cruz) and rabbit Anti-PABPC1
(SAB2101708, Sigma), rabbit anti Rpl26 (Ab59567, Abcam), rabbit anti S6 (2217, Cell Signaling Technology).
AlphaScreen assays
Recombinant HuD-His-HA proteins, expressed and purified from NSC-34 cells by Ni Sepharose beads (GE Healthcare), were tested
in saturation binding conditions using biotinylated ARE RNA (50-AUUAUUUAUUAUUUAUUUAUUAUUUA) or Y3 RNA probes and the
AlphaScreen Hemagglutinin detection kit (Perkin Elmer) with an optimized protocol already described (D’Agostino et al., 2013). Equi-
librium dissociation constants (Kd) were determined from nonlinear regression fits of the data according to a 1-site binding model in
GraphPad Prism, version 5.0 (GraphPad Software, Inc., San Diego, CA). The RNA binding activity of recombinant HuD proteins in cell
lysates was measured by reacting 50 nM of biotinylated probe upon determination of the assay specificity and hooking point.
Quantification of HuD and Y3 molecules
NSC-34 cells (5x106) were lysed using RIPA buffer and the protein concentration was determined using standard Bradford Protein
assay (Sigma). Known amount of cell lysates and HuD recombinant protein (a generous gift of Dr. Paolo Struffi, University of Trento)
were separated by 10% SDS-PAGE and transferred to nitrocellulose membrane. Samples were analyzed by western blotting using
rabbit anti-HuD antibody (sc-28299, Santa Cruz) and the optical density (OD) of the protein bands were quantified by ImageJ. To
estimate the number of HuDmolecules NSC-34 cells, a standard curve was generated by plotting the known amounts of HuD recom-
binant protein (15, 25, 50, 75 ng) on the x axis, and their respective OD values on the y axis. This reference plot was used to inferred
the amount of HuD protein in our NSC-34 lysate and calculate the amount for cell.
To estimate the number of Y3 molecules in NSC-34 cells, murine Y3 was synthesized by in vitro transcription. Total RNA was ex-
tracted from NSC-34 cells with Trizol (Sigma-Aldrich). The amount of RNA was normalized to the cell number and corrected for pu-
rification efficiencies. Then quantitative Northern Blots were performed to determine the amount of Y3 in NSC-34 total RNA by using
in vitro transcribed Y3 as a standard. Finally, the amount of Y3 per NSC-34 cell could be determined.
AHA assay
De novo synthesized proteins were quantified using the Click-iT AHA Alexa Fluor Protein Synthesis HCS Assay (Molecular Probes,
Life Technologies). In brief, NSC-34 cells were plated at density of 10,000 cells/well in 96-well plates for 24h. The cells were then
induced to overexpress HuD (a) or silenced for HuD (b) or silenced for Y3 (c) or subjected to HuD overexpression and Y3 silencinge8 Molecular Cell 71, 256–270.e1–e10, July 19, 2018
(d). After 48h, the cells were washed, incubated with L-azidohomoalanine (AHA) 50 mM for 1h and fixed. During AHA incorporation,
control cells were treated with puromycin (100 ug/ml), a protein synthesis inhibitor, to evaluate background labeling. Click-chemistry
reactions were sequentially performed according to the manufacturer’s instructions and the relative AHA incorporation was
then analyzed by high content imaging approach. To detect cell nuclei, the kit was multiplexed with Hoechst 33342. Plates
(96-well CellCarrier, PerkinElmer) were imaged on the High Content Screening System Operetta (PerkinElmer). In each well, images
were acquired in preselected fields with LWD 20x objective. For the feature extraction, the images were analyzed by Harmony soft-
ware version 4.1 (PerkinElmer). Based on the Hoechst dye and Alexa 488 fluorescence intensity, cell nuclei and cell cytoplasm were
identified respectively. To quantify nascent protein synthesis, themean fluorescence intensity of Alexa Fluor 488was quantified in the
cytoplasm.
QUANTIFICATION AND STATISTICAL ANALYSIS
CRAC data analysis
Adaptor removal and collapse of duplicate reads (also with identical random barcode, marking PCR duplicates) were performed with
hyb (https://github.com/gkudla/hyb). Reads were aligned to themouse genome (GRCm38.p4) with Tophat (version 2.0.14), using the
Gencode M6 transcript annotation as transcriptome guide. All programs were used with default settings unless otherwise specified.
In order to detect CRACbinding sites, we developed and implemented a dedicated computational methodology (MAPAS, standing
for Mutation And PWMAssisted Search) that takes advantage of cross-linking induced mutations, consisting primarily in deletions in
our experiment, in order to localize candidate binding sites. After the integration of replicates, to increase specificity, we penalized
locations with aligned reads and deletions in control experiments (noise subtraction and removal). For each of the remaining loca-
tions, we calculated a combined p value based on a) the number of deletions, b) the number of aligned reads (coverage). P values
were empirically calculated from the genome-wide experimental distributions of coverage and number of deletions. Coverage and
deletion p values were combined with the Fisher method.
A pool of 753 sequences surrounding unique genomic locations with a combined p value < 0.05 were selected to build a PWM
(Positional Weight Matrix), hence used as a ‘‘seed’’ matrix to score to all the other candidate binding sites. To create the seed
PWM, we defined a region spanning seven nucleotides around the deletion site. This size choice is based on previous crystallo-
graphic studies resolving the structure of the RRM1 and RRM2 domains of HuD bound to canonical AU rich elements. PWM analysis
was performed with functions implemented in the Biostrings R package. The seed PWM was used to score all deletion sites and
select high-confidence HuD bound sites. A PWM score threshold was chosen, based on the 95 percentile of scores obtained
from random heptamers. HuD ‘‘high confidence’’ binding sites were selected among those with i) PWM score > PWM score
threshold, ii) number of HuD deletions > = 3 (at least one for replicate), iii) number of aligned reads > = 6 (at least two for replicate).
This procedure identified 5153 high confidence HuD binding sites (Supplemental Information).
RNA-Seq and POL-Seq data analysis
For RNA-Seq and POL-Seq data of NSC-34 cells, after quality control (FastQC) reads generated from each sample were aligned to
the mouse genome (GRCm38.p4) with STAR (version 2.5.3a,–quantMode TranscriptomeSAM GeneCounts), using the Gencode M6
transcript annotation as transcriptome guide. Normalization with the TMM method and identification of genes with altered TE upon
HuD overexpression were performed with the edgeR package. The experiment was performed in biological duplicate.
TruSeq Targeted RNA Expression data analysis
TruSeq Targeted sequencing of 75 genes (including 70 HuD targets and 5 negative control genes) was performed to validate HuD
RNA interactome (RIP-Seq in NSC-34 cells) and to monitor expression variations of HuD targets upon HuD overexpression (total
RNA and polysomal RNA in NSC-34 cells), with the Illumina MiSeq platform. Raw counts were determined from the alignment of
reads to targeted gene sequences. For HuD overexpression assay, normalization with the TMM method and identification of differ-
entially expressed genes (p value < 0.05) were performed with the edgeR package. For the RIP-seq assay, negative control genes
were used as housekeeping and data were normalized for the geometric mean of their expression values. Experiments were per-
formed in biological triplicate.
Alternative polyadenylation data analysis
Transcriptome-wide alternative polyadenylation (APA) analysis upon HuD overexpression in NSC-34 cells was performed in biolog-
ical triplicate by 30end mRNA sequencing, using the Lexogen QuantSeq 30 mRNA-Seq Library Prep Kit REV.
After quality control (FastQC), reads generated from each sample were aligned to the mouse genome (GRCm38.p4) with STAR
(version 2.5.3a,–quantMode TranscriptomeSAM GeneCounts), using the Gencode M6 transcript annotation as transcriptome guide.
Polyadenylation site usage (pAu) values were determined counting the number of reads starting within 10 nucleotides from known
polyadenylation sites. Normalization and differential polyadenylation analysis were performed with the edgeR package.Molecular Cell 71, 256–270.e1–e10, July 19, 2018 e9
Functional annotation enrichment analysis
Functional annotation enrichment analysis with Gene Ontology terms, KEGG and REACTOME pathways were performed using the
clusterProfiler Bioconductor package.
Functional annotation enrichment analysis with lists of genes derived from experimental datasets was performed with the enrichR
gene set libraries.
Statistical analysis
Unless stated otherwise all quantitative experiments were performed in triplicate and average with standard error of the mean (SEM)
was reported in the corresponding figure legends. Analysis of data from sequencing and other experiments was carried out using
programs described in the Key Resources Table and corresponding sections in STAR Methods.
DATA AND SOFTWARE AVAILABILITY
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